Disappointing revenue from analytics services and does sound...

Disappointing revenue from analytics services and does sound like COVID has significantly impacted our commercialization efforts.
Anyone care to share their thought's on why they would shift manufacturing?

----------------
The necessity for clinical pathology laboratories to focus testing on the SARS-CoV-2 virus has naturally restricted testing for other diseases. This has presented limitations for the immediate rollout of the novel PromarkerD test, and there have been impacts in each country (Spain, Mexico, Dominican Republic, Italy, Israel) where Proteomics International has a licence or distribution
agreement.

Proteomics International believes that there is strong, pent-up demand for screening for major diseases neglected during the pandemic, including diabetes and its complications such as chronic kidney disease. Diagnostics companies will also be strongly positioned with additional testing
capacity, alongside a community now more aware of the importance of early testing for disease. Taken together, this has provided the opportunity for Proteomics International to prepare PromarkerD so that it is market ready as the pandemic comes under control. To this end Proteomics International is in discussions for the manufacture of PromarkerD to be relocated to the northern hemisphere, and is pursuing regulatory and reimbursement pathways in a number of jurisdictions. The Company will adjust timelines and provide details where they are material to achieving roll-outs in a specified time period.

----------------

This sounds very promising :

Important for the future commercial application of potential new PromarkerTM derived biomarkers, the above PromarkerD assay performance studies also illustrate the potential for adoption of Proteomics International's PromarkerTM mass spectrometry diagnostics platform in future clinical
practice. The Company has positioned its R&D arm at the forefront of this technological approach, which has the potential to overtake current immunoassay technology and assume mainstream use in clinical pathology laboratories. Exemplifying this, the Clinical Proteomics publication [ASX: 5 November] is one of the first validations of a proteomics derived multi-biomarker diagnostic test in a clinical setting.